{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:51Z","timestamp":1790906271660,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09302049"],"award-info":[{"award-number":["2018ZX09302049"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007322","name":"Binzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.exer.2019.107823","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T10:21:16Z","timestamp":1570443676000},"page":"107823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates"],"prefix":"10.1016","volume":"190","author":[{"given":"Jing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangying","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuandong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.107823_bib1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00417-013-2322-7","article-title":"The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Beh\u00e7et\u2019s disease","volume":"251","author":"Yal\u00e7\u0131nda\u011f","year":"2013","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107823_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.107823_bib5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema: evidence-based management","volume":"66","author":"Browning","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib7","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1167\/iovs.17-22431","article-title":"Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model","volume":"58","author":"Christoforidis","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.107823_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000320005","article-title":"Angiostatic and angiogenic factors. Angiostatic and angiogenic factors","volume":"46","author":"de Groot","year":"2010","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"Dixon","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.exer.2019.107823_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2016.04.036","article-title":"Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects","volume":"377","author":"Li","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.exer.2019.107823_bib11","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Elizabeth Hartnett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.107823_bib12","first-page":"393","article-title":"A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane","volume":"130","author":"Folkman","year":"1988","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2019.107823_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","article-title":"Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit","volume":"97","author":"Li","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2019.107823_bib14","first-page":"1","article-title":"New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion","volume":"2017","author":"Li","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.exer.2019.107823_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejps.2018.04.043","article-title":"Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2","volume":"121","author":"Jiang","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.exer.2019.107823_bib16","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2019.107823_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000320006","article-title":"Mechanisms of ocular angiogenesis and its molecular mediators","volume":"46","author":"Siemerinka","year":"2010","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcmd.2007.04.001","article-title":"Understanding the biology of angiogenesis: review of the most important molecular mechanisms","volume":"39","author":"Otroc","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.exer.2019.107823_bib19","first-page":"356","article-title":"Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy","volume":"23","author":"Paine","year":"2017","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2019.107823_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","article-title":"A multinational comparison of anti-vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific","volume":"3","author":"Parikh","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.exer.2019.107823_bib21","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.107823_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40942-016-0051-x","article-title":"Neovascular glaucoma: a review","volume":"2","author":"Rodrigues","year":"2016","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.exer.2019.107823_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000431129","article-title":"Ocular angiogenesis: vascular endothelial growth factor and other factors","volume":"55","author":"Rubio","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.exer.2019.107823_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"5","author":"Semeraro","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.exer.2019.107823_bib25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1389200216666151001120831","article-title":"Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection","volume":"16","author":"Semeraro","year":"2015","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.exer.2019.107823_bib26","first-page":"935","article-title":"Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina","volume":"11","author":"Yang","year":"2018","journal-title":"Int. J. Ophthalmol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519304920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519304920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:02:23Z","timestamp":1757998943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483519304920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":25,"alternative-id":["S0014483519304920"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.107823","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.107823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107823"}}